|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
39
|
|
pubmed:dateCreated |
2002-9-23
|
|
pubmed:abstractText |
Prenylated Rab acceptor (PRA1) is a protein that binds Rab GTPases and the v-SNARE VAMP2. The protein is localized to the Golgi complex and post-Golgi vesicles. To determine its functional role, we generated a number of point mutations and divided them into three classes based on cellular localization. Class A mutants were retained in the endoplasmic reticulum (ER) and exerted an inhibitory effect on transport of vesicular stomatitis virus envelope glycoprotein (VSVG) from the ER to Golgi as well as to the plasma membrane. Class B mutants exhibited a highly condensed Golgi complex and inhibited exit of anterograde cargo from this organelle. Class C mutants exhibited an intermediate phenotype with Golgi and ER localization along with extensive tubular structures emanating from the Golgi complex. There was a direct correlation between the cellular phenotype and binding to Rab and VAMP2. Class A and C mutants showed a significant decrease in Rab and VAMP2 binding, whereas an increase in binding was observed in the class B mutants. Thus, PRA1 is required for vesicle formation from the Golgi complex and might be involved in recruitment of Rab effectors and SNARE proteins during cargo sequestration.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0021-9258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
277
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
36408-14
|
|
pubmed:dateRevised |
2010-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:12107180-Animals,
pubmed-meshheading:12107180-Blotting, Western,
pubmed-meshheading:12107180-CHO Cells,
pubmed-meshheading:12107180-Carrier Proteins,
pubmed-meshheading:12107180-Cell Membrane,
pubmed-meshheading:12107180-Cricetinae,
pubmed-meshheading:12107180-Dose-Response Relationship, Drug,
pubmed-meshheading:12107180-GTP-Binding Proteins,
pubmed-meshheading:12107180-Golgi Apparatus,
pubmed-meshheading:12107180-Immunohistochemistry,
pubmed-meshheading:12107180-Membrane Proteins,
pubmed-meshheading:12107180-Microscopy, Fluorescence,
pubmed-meshheading:12107180-Mutagenesis, Site-Directed,
pubmed-meshheading:12107180-Mutation,
pubmed-meshheading:12107180-Phenotype,
pubmed-meshheading:12107180-Point Mutation,
pubmed-meshheading:12107180-Protein Binding,
pubmed-meshheading:12107180-SNARE Proteins,
pubmed-meshheading:12107180-Temperature,
pubmed-meshheading:12107180-Time Factors,
pubmed-meshheading:12107180-Transfection,
pubmed-meshheading:12107180-Two-Hybrid System Techniques,
pubmed-meshheading:12107180-Vesicular Transport Proteins
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Disruption of Golgi morphology and trafficking in cells expressing mutant prenylated rab acceptor-1.
|
|
pubmed:affiliation |
Ottawa Health Research Institute, Cellular & Molecular Medicine, University of Ottawa, Ottawa, Ontario K1Y 4E9, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
